Fosamax Femur Fracture Lawsuit
Fosamax linked to more problems

Fosamax, a bisphosphonate drug, was first approved by the Food and Drug Administration (FDA) in 1995 to treat osteoporosis in women. However, users of the drug claim a linkage between Fosamax and fractures and are now pursuing compensation in a class action lawsuit.

The drug has also been linked to other problems as well. Users of the popular drug claim that Fosamax causes severe muscle pain and/or osteonecrosis of the jaw (ONJ) or “dead jaw.”

Merck & Co., manufacturer of Fosamax, responds to these claims by stating that in their own clinical trials, these side effects were questionable.

Merck released a statement which said "In worldwide post-marketing experience with Fosamax, Fosamax Plus D, rare reports consistent with osteonecrosis of the jaw have been received. Many of these reports lack sufficient clinical details to make definitive assessments or are confounded, particularly since a generally accepted definition of ONJ in the general population is unknown."

Users of the drug Fosamax are currently in the process of filing lawsuits against drug maker Merck & Co. Researchers who have studied Fosamax are convinced that the drug does in fact cause femur fractures since it is shown to slow down the rate at which the human body replaces old bones with new, causing micro fractures to eventually become major fractures.

In 2008, the Food and Drug Administration issued a medical advisory warning doctors and patients about the side effects of Fosamax use. Two years later, the FDA mandated new warning labels for all bisphosphonate drugs.

Those who have taken the drug continue to pursue compensation by filing Fosamax femur fracture lawsuits against Merck & Co. Victims accuse the drug company of failing to properly warn about the risks associated with long term use of Fosamax.

The next case hearing against Merck & Co. is scheduled for February 2012.




About the Contributor

Related Posts